Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates - PubMed
- ️Wed Jan 01 2020
Clinical Trial
. 2020 Dec 17;383(25):2439-2450.
doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
Robert W Frenck Jr 1 , Ann R Falsey 1 , Nicholas Kitchin 1 , Judith Absalon 1 , Alejandra Gurtman 1 , Stephen Lockhart 1 , Kathleen Neuzil 1 , Mark J Mulligan 1 , Ruth Bailey 1 , Kena A Swanson 1 , Ping Li 1 , Kenneth Koury 1 , Warren Kalina 1 , David Cooper 1 , Camila Fontes-Garfias 1 , Pei-Yong Shi 1 , Özlem Türeci 1 , Kristin R Tompkins 1 , Kirsten E Lyke 1 , Vanessa Raabe 1 , Philip R Dormitzer 1 , Kathrin U Jansen 1 , Uğur Şahin 1 , William C Gruber 1
Affiliations
- PMID: 33053279
- PMCID: PMC7583697
- DOI: 10.1056/NEJMoa2027906
Clinical Trial
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E Walsh et al. N Engl J Med. 2020.
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no vaccine is currently available. Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States.
Methods: In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States, we randomly assigned healthy adults 18 to 55 years of age and those 65 to 85 years of age to receive either placebo or one of two lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain; or BNT162b2, which encodes a membrane-anchored SARS-CoV-2 full-length spike, stabilized in the prefusion conformation. The primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity was a secondary outcome. Trial groups were defined according to vaccine candidate, age of the participants, and vaccine dose level (10 μg, 20 μg, 30 μg, and 100 μg). In all groups but one, participants received two doses, with a 21-day interval between doses; in one group (100 μg of BNT162b1), participants received one dose.
Results: A total of 195 participants underwent randomization. In each of 13 groups of 15 participants, 12 participants received vaccine and 3 received placebo. BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults. In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers, which were similar to or higher than the geometric mean titer of a panel of SARS-CoV-2 convalescent serum samples.
Conclusions: The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Copyright © 2020 Massachusetts Medical Society.
Figures

The 54 participants who were not assigned to a trial group were screened but did not undergo randomization because trial enrollment had closed. All the participants received two doses of the vaccine (BNT162b1 or BNT162b2) or placebo, except for the participants who were assigned to receive 100 μg of BNT162b1 or placebo, who received one dose.

Panel A shows local reactions in participants 18 to 55 years of age, and Panel B those in participants 65 to 85 years of age. Injection-site (local) reactions were recorded in electronic diaries for 7 days after each injection. Pain at the injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity), or grade 4 (led to an emergency department visit or hospitalization). Redness and swelling were graded as mild (2.0 to 5.0 cm in diameter), moderate (>5.0 to 10.0 cm in diameter), severe (>10.0 cm in diameter), or grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). 𝙸 bars represent 95% confidence intervals. The numbers above the 𝙸 bars show the overall percentage of the participants in each group who reported the specified local reaction. No participant who received either vaccine candidate reported a grade 4 local reaction.

Panel A shows systemic reactions in participants 18 to 55 years of age, and Panel B those in participants 65 to 85 years of age. Data on fever, chills, and fatigue are reported here. (Data on headache, vomiting, diarrhea, muscle pain, and joint pain are reported in Fig. S1.) Data on systemic events were recorded in electronic diaries for 7 days after each injection. The fever scale is shown in the key. Chills and fatigue were graded as being mild (does not interfere with activity), moderate (interferes somewhat with activity), severe (prevents daily activity), or grade 4 (led to an emergency department visit or hospitalization). 𝙸 bars represent 95% confidence intervals. The numbers above the 𝙸 bars show the overall percentage of participants in each group who reported the specified systemic event. No participant who received either vaccine candidate reported a grade 4 systemic event or a temperature higher than 40.0°C.

Participants in groups of 15 received an injection with the indicated dose levels of one of either of the BNT162 vaccine candidates (12 participants) or placebo (3 participants) on days 1 and 21. Arrows indicate days of vaccination. Responses in the placebo recipients in each of the dose-level groups are combined. Serum samples were obtained before injection (on day 1) and on days 21, 28, and 35 after the first dose. The blood samples obtained on days 28 and 35 are those obtained 7 days and 14 days, respectively, after the second dose. Human coronavirus disease 2019 (Covid-19) or SARS-CoV-2 infection convalescent serum (HCS) samples were obtained from 38 donors at least 14 days after polymerase chain reaction–confirmed diagnosis and at a time when the donors were asymptomatic. Panel A shows the geometric mean concentrations of recombinant S1-binding IgG (lower limit of quantitation, 1.267; dashed line), and Panel B the 50% SARS-CoV-2–neutralizing geometric mean titers (lower limit of quantitation, 20; dashed line). On days that vaccine or placebo was administered, samples were obtained before the injection. Each data point represents a serum sample, and the top of each vertical bar represents the geometric mean with the 95% confidence interval (𝙸 bar). Data points associated with placebo, HCS samples, or the 10-μg dose of vaccine are shown as circles, those for the 20-μg dose as squares, and those for the 30-μg dose as triangles. The numbers above the bars show the geometric mean concentration or geometric mean titer in the group. All the vaccine groups had 12 valid results from samples that could be evaluated at each time point except for the following: among participants who received BNT162b2, 11 results from day 28 in younger participants who received 30 μg, 10 results from day 35 in younger participants who received 30 μg, and 11 results from day 35 in older participants who received 10 μg.
Update of
-
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.
Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Thompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Sahin U, Gruber WC. Walsh EE, et al. medRxiv [Preprint]. 2020 Aug 28:2020.08.17.20176651. doi: 10.1101/2020.08.17.20176651. medRxiv. 2020. PMID: 32839784 Free PMC article. Updated. Preprint.
Comment in
-
Chavarot N, Ouedrani A, Marion O, Leruez-Ville M, Vilain E, Baaziz M, Del Bello A, Burger C, Sberro-Soussan R, Martinez F, Chatenoud L, Abravanel F, Anglicheau D, Izopet J, Couat C, Zuber J, Legendre C, Lanternier F, Kamar N, Scemla A. Chavarot N, et al. Transplantation. 2021 Sep 1;105(9):e94-e95. doi: 10.1097/TP.0000000000003784. Transplantation. 2021. PMID: 33831941 No abstract available.
Similar articles
-
Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, Ji R, Lin M, Zhu Z, Türeci Ö, Lagkadinou E, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Şahin U, Zhu L, Zhu F. Li J, et al. Nat Med. 2021 Jun;27(6):1062-1070. doi: 10.1038/s41591-021-01330-9. Epub 2021 Apr 22. Nat Med. 2021. PMID: 33888900 Clinical Trial.
-
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.
Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Thompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Sahin U, Gruber WC. Walsh EE, et al. medRxiv [Preprint]. 2020 Aug 28:2020.08.17.20176651. doi: 10.1101/2020.08.17.20176651. medRxiv. 2020. PMID: 32839784 Free PMC article. Updated. Preprint.
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Polack FP, et al. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. N Engl J Med. 2020. PMID: 33301246 Free PMC article. Clinical Trial.
-
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. Meo SA, et al. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
Khehra N, Padda I, Jaferi U, Atwal H, Narain S, Parmar MS. Khehra N, et al. AAPS PharmSciTech. 2021 Jun 7;22(5):172. doi: 10.1208/s12249-021-02058-y. AAPS PharmSciTech. 2021. PMID: 34100150 Free PMC article. Review.
Cited by
-
Meira C, Silva D, Santos I, Barreto B, Rocha V, Santos E, Dos Reis B, Evangelista A, Ribeiro Dos Santos R, Machado B, Ribeiro G, Badaró R, Soares M. Meira C, et al. ScientificWorldJournal. 2022 Aug 16;2022:7754329. doi: 10.1155/2022/7754329. eCollection 2022. ScientificWorldJournal. 2022. PMID: 36017468 Free PMC article.
-
Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, Lee MS, Hong SJ, Choi BY, Lee SS, Back HJ; Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with Autoimmune Inflammatory Rheumatic Diseases. Park JK, et al. J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95. J Korean Med Sci. 2021. PMID: 33783147 Free PMC article. Review.
-
Venkataraman S. Venkataraman S. Vaccines (Basel). 2022 Oct 26;10(11):1805. doi: 10.3390/vaccines10111805. Vaccines (Basel). 2022. PMID: 36366313 Free PMC article. Review.
-
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.
Li J, Liu Q, Liu J, Fang Z, Luo L, Li S, Lei Y, Li Z, Jin J, Xie R, Peng Y. Li J, et al. Vaccines (Basel). 2022 Oct 26;10(11):1807. doi: 10.3390/vaccines10111807. Vaccines (Basel). 2022. PMID: 36366316 Free PMC article.
-
Zare H, Rezapour H, Fereidouni A, Nikpour S, Mahmoudzadeh S, Royce SG, Fereidouni M. Zare H, et al. Immun Ageing. 2022 Oct 22;19(1):47. doi: 10.1186/s12979-022-00303-x. Immun Ageing. 2022. PMID: 36273175 Free PMC article.
References
-
- Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2020 (https://coronavirus.jhu.edu/map.html).
-
- Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature 2020. September 30 (Epub ahead of print). - PubMed
-
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020. August 12 (Epub ahead of print). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous